Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ENSC vs BFRI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
ENSC Captures Overall Composite Edge (53.4 HOLD vs 44.0 HOLD), While BFRI Leads 3–1 on Growth & Valuation Pillars
ENSC Overall Winner
6-Pillar Tally: ENSC 1 – 3 BFRI (2 Tie)
Matrix Metrics: ENSC 5 – 4 BFRI
As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Biofrontera Inc. (BFRI) on higher Unified Composite conviction (53.4/100 HOLD vs. 44.0/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples), while BFRI wins 3–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus BFRI at $0.53 (13.0x Forward P/E, -12.6% operating margin).
- Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. BFRI 44.0/100 HOLD) and 0.98β · 79% Vol risk profile, whereas BFRI leads top-line expansion (+29.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
- Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile BFRI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About ENSC vs BFRI
ENSC
Head-to-Head Winner
Ensysce Biosciences, Inc. Common Stock
$0.36
-0.17% 1D
Market Cap
$7.0M
TTM Revenue
$4.5M
Forward P/E
0.8x
Beta / 30D Vol
0.98β · 79% Vol
Unified Composite Score
53.4
HOLD
Tech 50.0
Fund 62.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
BFRI
Biofrontera Inc. Common Stock
$0.53
-7.02% 1D
Market Cap
$10.2M
TTM Revenue
$48M
Forward P/E
13.0x
Beta / 30D Vol
1.84β · 125% Vol
Unified Composite Score
44.0
HOLD
Tech 25.0
Fund 42.0
Flow 50.0
Mom 59.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (ENSC 1 – 3 BFRI)
1. Valuation Multiples
ENSC
Forward P/E
0.8x
13.0x
Trailing P/E
0.8x
13.0x
PEG Ratio
N/M
N/M
EV / Revenue
1.4x
0.2x
2. Growth & Scale
BFRI
Revenue Growth (YoY)
-15.1%
+29.8%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$4.5M
$48M
Market Cap
$7.0M
$10.2M
3. Profitability & Quality
BFRI
Gross Margin
N/A
79.6%
Operating Margin
-281.3%
-12.6%
Net Profit Margin
-280.5%
-12.7%
Return on Equity (ROE)
-1295.1%
-988.4%
4. Balance Sheet & Cash Flow
BFRI
Cash Generation (TTM)
-$9.7M
-$9.3M
Cash Flow Margin
N/A
-19.3%
Net Cash / Leverage
-$499,633 Net Debt
$1.4M Net Debt (1.27x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Drug Manufacturers - Specialty & Generic Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: ENSC (5) vs BFRI (4)| Institutional Metric | ENSC | BFRI | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $7.0M | $10.2M | Tie | |
| Trailing P/E Ratio | 0.8x | 13.0x | ENSC | |
| Forward P/E Ratio | 0.8x | 13.0x | ENSC | |
| Revenue Growth (YoY) | -15.1% | +29.8% | BFRI | |
| Operating Margin (TTM) | -281.3% | -12.6% | BFRI | |
| Net Profit Margin | -280.5% | -12.7% | BFRI | |
| Return on Equity (ROE) | -1295.1% | -988.4% | BFRI | |
| 52-Week Range Position | 8% ($0–$2) | 0% ($1–$2) | ENSC | |
| Beta / 30D Volatility | 0.98β · 79% Vol | 1.84β · 125% Vol | ENSC | |
| Unified Institutional Score | 53.4 / 100 (HOLD) | 44.0 / 100 (HOLD) | ENSC | |
| Trailing 12M Revenue (USD) | $4.5M | $48M | Scale | |
| Gross Profit Margin (TTM) | N/A | 79.6% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 1.4x EV/Rev | N/M PEG · 0.2x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$9.7M (-$499,633 Net Debt) | -$9.3M ($1.4M Net Debt (1.27x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
ENSC +2.59 pp
3M Horizon
ENSC +63.42 pp
6M Horizon
ENSC +47.34 pp
1Y Horizon
BFRI +45.84 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ENSC Revenue | BFRI Revenue | ENSC Op. Margin | BFRI Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2020 | $0M | $20M | -41.0% | -51.0% | ENSC |
| FY2021 | $0M | $20M | -562.7% | -104.6% | BFRI |
| FY2022 | $0M | $30M | -959.9% | -64.8% | BFRI |
| FY2023 | $0M | $30M | -480.5% | -66.6% | BFRI |
| FY2024 | $10M | $40M | -129.2% | -46.1% | BFRI |
| FY2025 | $10M | $40M | -202.1% | -27.2% | BFRI |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
ENSC
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BFRI
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact BFRI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
ENSC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BFRI Moat Profile
Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ ENSC vs BFRI Key Questions & Quantitative Answers
As of Nov 20, 2026, Ensysce Biosciences, Inc. (ENSC) captures the overall head-to-head institutional edge over Biofrontera Inc. (BFRI) on higher Unified Composite conviction (53.4/100 HOLD vs. 44.0/100 HOLD) after splitting the core matrix 5–4 (led by Valuation Multiples), while BFRI wins 3–1 across the 6-pillar growth and valuation breakdown. ENSC trades at $0.36 (0.8x Forward P/E, -281.3% operating margin) versus BFRI at $0.53 (13.0x Forward P/E, -12.6% operating margin). Growth vs. Quality Trade-Off: ENSC earns the overall head-to-head edge with a stronger Unified Composite Score (53.4/100 HOLD vs. BFRI 44.0/100 HOLD) and 0.98β · 79% Vol risk profile, whereas BFRI leads top-line expansion (+29.8% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ENSC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7); meanwhile BFRI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 27.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BFRI leads the Growth & Scale pillar: ENSC posts -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin), compared with BFRI at +29.8% YoY revenue growth and +0.0% YoY earnings growth on $48M TTM revenue (79.6% gross margin, -12.6% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), ENSC cumulative revenue shifted +0.0% while BFRI shifted +100.0%. In operating R&D and SG&A reinvestment, ENSC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BFRI.
ENSC screens cheaper on headline valuation multiples. ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin), whereas BFRI trades at 13.0x Forward P/E, 13.0x Trailing P/E, N/M PEG, and 0.2x EV/Revenue (-19.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENSC (-1295.1% ROE) versus BFRI (-988.4% ROE) capital efficiency.
In options market volatility and institutional positioning, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk). By comparison, BFRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.84β · 125% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BFRI vs ENSC · Reverse Pair
ENSC vs QNRX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal